We see potential come to life.

We’re inspired to identify and develop therapies from a different perspective to answer the unmet needs of people impacted by neurologic conditions. Infused with a spirit of innovation, we’re willing to take risks and explore new paths forward. We’re motivated by the idea of seeing the world as it should be—and making it a reality.

Our Pipeline

Our Trials

Our News

Our Compounds




Our lead investigational drug candidate

Intepirdine is an orally administered, potent antagonist of the 5HT6 receptor.

More about intepirdine


Our second investigational drug candidate

Nelotanserin is a potent and highly selective inverse agonist of the 5HT2A receptor.

More about nelotanserin

At Axovant, we pride ourselves on creating an environment in which we are able to do our best work while maintaining the highest standards of business conduct and ethics.

—David Hung, MD
Chief Executive Officer

Meet Our Leadership Team

Alzheimer's Disease

Alzheimer's disease, the most common form of dementia, is a chronic, progressive neurodegenerative disorderi

Learn More

Lewy Body Dementia

Lewy body dementia (LBD) is a progressive brain disorder in which Lewy bodies, abnormal deposits of a protein called alpha-synuclein, build up in areas of the brain that regulate behavior, cognition and movement.ii

Learn More


  1. Alzheimer's Association. 2017 Alzheimer’s disease facts and figures. https://www.alz.org/documents_custom/2017-facts-and-figures.pdf. Accessed August 15, 2017.
  2. Lewy Body Dementia Association. What is Lewy body dementia? https://www.lbda.org/category/3437/what-is-lbd.htm. Accessed August 15, 2017.